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Gregory L. Moneta, MD, Section EditorEffect of Statin Therapy on Mortality in Patients with Peripheral
Arterial Disease and Comparison of those With versus Without Asso-
ciated Chronic Obstructive Pulmonary Disease
Dangestel YRBM, Hoeks SE, Sin DD, et al. Am J Cardiol 2008;102:192-6.
Conclusions:Low-dose and intensive statin therapy are both beneficial
in prolonging long-term survival in patients with peripheral arterial disease
(PAD). Short-term survival is also improved in patients with chronic ob-
structive pulmonary disease (COPD) using intensified statin dosages.
Summary: PAD and COPD are both characterized by inflammation.
Statins have an anti-inflammatory effect and are commonly used in patients
with PAD. Because COPD also has an inflammatory component, statins may
be beneficial in patients with COPD as well. The authors investigated the
relationship between mortality and statin use in patients with PAD with and
without COPD.
There were 3371 vascular surgery patients studied from 1990 to 2006.
Statin use was noted at baseline. When statins were prescribed, it was noted
whether the dose was25% of themaximum recommended dose (low dose)
or 25% of the maximum recommended therapeutic dose (intensified
dose). COPD diagnosis was based on pulmonary function testing. Survival
was analyzed in both the short- (30 days) and long-term (10 years). Statins
were used by 330 patients with COPD and 480 patients without COPD.
Statin use was independently associated with improved short- and long-term
survival in patients with COPD (odds ratio [OR], 0.48; 95% confidence
interval [CI], 0.23-1.00; hazard ratio [HR], 0.67; 95% CI, 0.52-0.86,
respectively). Statins were also associated with improved short- and long-
term survival in patients without COPD (OR, 0.42; 95% CI, 0.2-0.87; HR,
0.76; 95% CI, 0.60-0.95, respectively). Only intensive statin therapy was
associated with improved short-term survival in patients with COPD. Long-
term, both low-dose and intensive statin therapy were beneficial.
Comment: This study confirms the known beneficial effects of statins
on long- and short-term mortality in patients with PAD. We are now,
however, beginning to get data regarding dosages of statin therapy that may
be appropriate to extend survival in patients with PAD. There may be a
cohort of patients, such as those with COPD, whose short-term survival will
be improved by a more intensive dose of statins than generally may be
required.
A Ten-Year Analysis of Venous Thromboembolism on the Surgical
Service: The Effect of Practice Guidelines for Prophylaxis
Shackford SR, Rogers FB, Terrien CM. Surgery 2008;144:3-11.
Conclusion: High compliance with the American College of Chest
Physicians (ACCP) Guidelines for Prophylaxis for Venous Thromboembolism
has not resulted in a decrease in symptomatic venous thromboembolism
(VTE) in surgical patients.
Summary: The ACCP has published its Guidelines for Prophylaxis for
Venous Thromboembolism about every 3 years since 1995, with the most
recent version published in August 2008. There is currently intense interest
in proving compliance with these guidelines to reduce the incidence of VTE
in hospitalized patients. The effect on surgical patients of compliance or
noncompliance with prophylaxis guidelines for VTE on morbidity and
mortality is not known.
In this series the authors sought to determine whether a decrease
occurred in symptomatic VTE on their general surgical, vascular surgical,
and trauma services since initial publication of the VTE prophylaxis guide-
lines. Care of patients with symptomatic VTE was analyzed for compliance
or noncompliance with the guidelines, and reasons for noncompliance. The
effect of VTE on short-term morbidity and mortality was also analyzed. The
study used records of patients with symptomatic VTE on the general
surgical, vascular surgical, and trauma surgical services at the University of
Vermont for a 10-year period since publication of the 1995 ACCP guide-
lines. Morbidity of each episode of VTEwas weighted based on likelihood of
short-term mortality and long-term morbidity.
There were 37,615 patients on the combined surgical services during
the 10-year period of analysis, and a symptomatic VTE developed in 172
(0.46%). The incidence gradually increased during the years of the study.
Partial or complete compliance with the guidelines was achieved in 84% of
the patients. Of the VTEs that occurred, 37% were considered to be
preventable, whereas 63% were judged nonpreventable based on full com-
pliance with the guidelines or partial compliance associated with a docu-
mented contraindication to prophylaxis.
Comment: The authors report one of the highest rates of compliance
with ACCP guidelines for prophylaxis of VTE. Despite this, their rate of
symptomatic VTE has increased during the 10-year period of the study. A
1062number of factors may play a role in this increased incidence of symptomatic
VTE. These include more aggressive pursuit of the diagnosis of pulmonary
embolism or deep venous thrombosis and an increase in the comorbidity
burden of patients undergoing surgical treatment. There is also the possi-
bility that the prophylactic measures suggested by the guidelines are insuf-
ficient to prevent VTE in some high-risk patients.
Activated Partial Thromboplastin Time and Risk of Future Venous
Thromboembolism
Zakai NA, Ohira T, White R, et al. Am J Med 2008;121:231-8.
Conclusion: A single determination of activated partial thromboplas-
tin time (aPTT) below the median is a marker of increased risk of future
venous thromboembolism (VTE).
Summary:Higher levels of coagulation factors may be associated with
lower aPTTs. A lower aPTT therefore may present a relative hypercoagula-
ble state. The authors used patients from the Atherosclerotic Risk in Com-
munity Study to study the 13-year risk of VTE with respect to aPTT. The
analysis included 13,880 individuals. There were 258 cases of VTE and 589
matched controls where additional coagulation factors were measured. With
adjustment for procoagulant factors reflected in the aPTT (factors VIII, IX,
and XI, fibrinogen, and von Willebrand factor) and after adjustment for
demographics, study participants in the lowest two quartiles of aPTT com-
pared with the fourth quartile had a twofold (95% confidence interval [CI],
1.4-4.2) and 1.9-fold (95% CI, 1.1-3.2) increased risk of VTE. The risk
associated with an aPTT below the median was higher for idiopathic vs
secondary VTE (odds ratio, 5.5; 95% CI, 2.0-15.5; and odds ratio, 1.75;
95% CI, 0.88-3.43, respectively). Subjects who had both a factor V Leiden
mutation and an aPTT below the median were at high risk of developing
VTE compared with those with neither risk factor (12.6-fold, 95% CI,
5.7-28.0, P  .01 for interaction). A lowered aPTT also added to throm-
botic risk associated with obesity and elevated D-dimer.
Comment: Lower activated aPTTs have long been suspected to be
indicative of a relative hypercoagulable state. The question has been how
hypercoagulable? This important study helps quantify the risk of a decreased
aPTT. The information presented here should be immediately useful in
evaluating patients with VTE and perhaps also for prophylaxis of VTE in
at-risk patients. It appears patients with VTE and lowered aPTTs should be
considered for longer periods of anticoagulation to treat their VTE event.
Further study of high-risk groups, such as those with situational or perma-
nent risk factors for VTE, will be needed to see whether lower aPTTs are
truly useful in stratifying risk for initial VTE.
Assessment of Renal Artery Stenosis: Side-By-Side comparison of An-
giography andDuplexUltrasound with Pressure GradientMeasurements
Drieghe B, Madaric J, Sarno G, et al. Eur Heart J 2008;29:517-24.
Conclusion: Angiography and duplex ultrasound overestimate the
severity of renal artery stenosis compared with invasive measurements of
pressure gradients.
Summary: The authors evaluated 56 renal artery lesions with invasive
pressure measurements, angiography, and duplex ultrasound. They corre-
lated pressure gradients with angiographic and duplex ultrasound parame-
ters. They used a distal renal artery pressure to aortic pressure (Pd/Pa)0.90
as a standard for finding a significant renal artery stenosis (RAS). Pressure
measurements were made with a 0.014-inch pressure wire. Angiographic
variables assessed included percentage of diameter stenosis and minimal
luminal diameter. Duplex-derived parameters included peak systolic
velocity (PSV), end diastolic velocity (EDV), and renal artery/aortic PSV
ratio.
The best correlation with pressure gradient measurements occurred
with duplex-determined EDV (r  –0.621). In identifying a stenosis
associated with a Pd/Pa 0.90, the diagnostic accuracy of angiographically
determined 50% stenosis, minimal lumen diameter 2 mm, and duplex
derived PSV180 cm/s, EDV90 cm/s, and renal artery/aortic PSV ratio
3.5 were, respectively, 60%, 77%, 45%, 77%, and 79%. False-positives were
38%, 15%, 55%, 11%, and 15%, respectively.
Comment: Basically, this study says angiographic and duplex criteria
for RAS will have many false-positive results compared with measured
pressure gradients. The authors therefore propose revised duplex criteria for
hemodynamically significant lesions based on pressure gradients. In partic-
ular, they suggest a renal aortic ratio 3.74 will have a 92% positive
predictive value in predicting a RAS with a significant pressure gradient.
Also, a minimal angiographic lumen 1.74 mm will have a 91% predictive
